These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12296365)

  • 21. Hormone replacement therapy. Current controversies.
    Burkman RT
    Minerva Ginecol; 2003 Apr; 55(2):107-16. PubMed ID: 12711997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women.
    Mosca L; Appel LJ; Benjamin EJ; Berra K; Chandra-Strobos N; Fabumni RP; Grady D; Haan CK; Hayes SN; Judelson DR; Keenan NL; McBride P; Oparil S; Ouyang P; Oz MC; Mendelsohn ME; Pasternak RC; Pinn VW; Robertson RM; Schenck-Gustafsson K; Sila CA; Smith SC; Sopko G; Taylor AL; Walsh BW; Wenger NK; Williams CL;
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):394-6. PubMed ID: 15003972
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cardiovascular disease and hormone replacement therapy].
    Aldrighi JM; Martinez TL; da Silva Filho CP
    Arq Bras Cardiol; 1995 Sep; 65(3):249-54. PubMed ID: 8579513
    [No Abstract]   [Full Text] [Related]  

  • 24. Another chapter in the heart and estrogen story.
    Harv Womens Health Watch; 2001 Apr; 8(8):1-2. PubMed ID: 11340038
    [No Abstract]   [Full Text] [Related]  

  • 25. Critical comments.
    Samsioe G; Neves-e-Castro M; Pines A; Doeren M; Utian WH; Jaffe RB; Genazzani AR; van der Mooren MJ
    Maturitas; 2001 Oct; 40(1):5-15. PubMed ID: 11684369
    [No Abstract]   [Full Text] [Related]  

  • 26. Estrogen for heart disease: risk or benefit?
    Harv Womens Health Watch; 2000 Jun; 7(10):1-2. PubMed ID: 10810060
    [No Abstract]   [Full Text] [Related]  

  • 27. Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review.
    Abramson BL
    J Cardiovasc Risk; 2002 Dec; 9(6):309-14. PubMed ID: 12478199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Further recognize the benefit and risk of postmenopausal hormone replacement therapy on atherosclerotic cardiovascular diseases].
    Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):321-3. PubMed ID: 12947970
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimizing the dose of hormone replacement therapy.
    Rice VM
    Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Postmenopausal hormone therapy and cognitive function change].
    Sun YM; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):423-4. PubMed ID: 15312332
    [No Abstract]   [Full Text] [Related]  

  • 31. Toward optimal health: the experts discuss cardiovascular disease. Interviewed by Jodi R. Godfrey.
    Bairey Merz CN; Hayes SN
    J Womens Health (Larchmt); 2005; 14(1):4-10. PubMed ID: 15692270
    [No Abstract]   [Full Text] [Related]  

  • 32. Hormone replacement therapy and cardiovascular disease.
    McPherson R; Tardif JC; Jolly E
    Can J Cardiol; 2001 Nov; 17 Suppl D():32D-37D. PubMed ID: 11726994
    [No Abstract]   [Full Text] [Related]  

  • 33. The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence.
    Barrett-Connor E
    Maturitas; 1996 Mar; 23(2):227-34. PubMed ID: 8735360
    [No Abstract]   [Full Text] [Related]  

  • 34. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM; Brinton EA; Cedars M; Lobo R; Manson JE; Merriam GR; Miller VM; Naftolin F; Santoro N
    Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
    Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice.
    Hendrix SL
    J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S3-5. PubMed ID: 12625631
    [No Abstract]   [Full Text] [Related]  

  • 38. Heart association issues new guidelines on cardiovascular disease prevention in women.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Feb; 15(4):1-2, 6-7. PubMed ID: 15000094
    [No Abstract]   [Full Text] [Related]  

  • 39. [Joint position statement of Polish Gynecologic Society, Polish Cardiological Society, and Polish Menopause and Andropause Society on the effect of hormone replacement therapy on cardiovascular system].
    Kornacewicz-Jach Z; Czarnecka D; Rynkiewicz A; Kotarski J; Paszkowski T; Pertyński T; Debski R; Wielgoś M
    Kardiol Pol; 2009 Jan; 67(1):72-6. PubMed ID: 19253195
    [No Abstract]   [Full Text] [Related]  

  • 40. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.